Tweets and Retweets by @AVIVA1950 and by @pharma_BI for @USAIC and #USAIC2019 at the 13th Annual BioPharma & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA
-
You Retweeted
Alise Reicin
@Celgene#USAIC13@Boston discusses endpoints needed in#oncology#clinicaltrials and effect of cost of#drugdevelopment in Panel Discussion morning Networking break@Boston@BiotechWkBoston@Pharma_BI@AVIVA1950 -
You Retweeted
Alise Reicin
@Celgene#USAIC13@Boston Panel Discussion:#melanoma#trials best done as Basket&Umbrella trial; response rate@Merck#Keytruda 30-50% but Phase3 negative@BiotechWkBoston@Pharma_BI@Aviva1950Translate Tweet
-
You Retweeted
Dr. William Chin
@HarvardChanSPH@harvardmed#clinicaltrials design challenges with newer#biotech#DNA#therapies in recruiting patients; use Basket&Umbrella Trial design Live@BiotechWkBoston#USAIC13@Pharma_BI@AVIVA1950
On risk | benefit: Long term impacts of treatment may be present for the life of the patient @DrMRosenblatt @USAIC #USAIC19
-
-
-
-
You Retweeted
Discussion of cyber security at
#USAIC19 panel moderated by@Venkat101– realization that everything is interconnected: risks to business-critical functions. Much to learn from FinTech & others’ prior experience. -
You Retweeted
Unexpected best thing about
#USAIC19 – at least three Zimbabweans in the crowd / on the stage.#rarebirds -
You Retweeted
Most humbling & touching moment: meeting an exec who nodded & teared up as I told him what we do
@revealpharma His 9 yo child needs frequent contrast enhanced MRI scans for a rare disease. We felt like the smallest co at#USAIC19 yet so important for hope & health#whywedoit -
-
You Retweeted
Great initiatives to bring CAR-T to India an automation to drug manufacturion
@Pharma_BI@AVIVA1950Amazing moderator asking provoking question of best panel in
#BioPharma responses by experts made known were different for competing rivals the aim is same best#Therapies faster largest#access at lowest#price keeping#profit maximized@USAIC#USAIC2019@AVIVA1950@Pharma_BI -
-
You Retweeted
Dr. Bruce Chabner
@MGHMedicine@USAIC@Boston Talk: Old Phase 1,2,3#trial design not needed for#genomics &#precisionmedicine era based#therapies.@FDA very accommodating in Phase 1 trial design.#usaic2019@pharma_BI@AVIVA1950@BiotechWkBoston
-
You Retweeted
Dr. Bruce Chabner
@MGHMedicine@USAIC@Boston panel discussion:#oncology#clinicaltrial#patient selection based on new design paradigm; 40#chemo drugs approved by accelerated approval for#lungcancer#renalcancer#usaic2019@Pharma_BI@AVIVA1950@BiotechWkBoston#endcancer -
You Retweeted
Dr. Mace Rothenberg
@pfizer talks@USAIC#usaic2019@boston#regulation for#drug approvals vary greatly over multiple countries makes issues of ong-term#clinicaltrial design and post approval reimbursement@Pharma_BI@AVIVA1950@BiotechWkBoston -
You Retweeted
@DrMRosenblatt@FlagshipPioneer Talk@USAIC#usaic2019:#clinicaltrial design now depends on#drugdelivery systems e.g. organelle delivery.#pharma only wants accelerated approval not conditional approval. Surrogate markers critical for new trial design@Pharma_BI@AVIVA1950 -
You Retweeted
Dr. Rob Scott
@abbvie Panel Talk@USAIC#usaic2019#drugdevelopment crisis in#CVD not in#cancer. Lowest investment in#cardiovascular#drug development. Physicians using SAME design for#clinicaltrials.#digital use in trails increasing@Pharma_BI@AVIVA1950
-
You Retweeted
Dr. Rob Scott
@abbvie on#clinicaltrial design@USAIC @usaic2019: Regulators as partners not barriers but burden of efficacy on#pharma. Can use advertising to increase recruitment as 70% willing participants live too far away so use#telecom &#digital@Pharma_BI@AVIVA1950 -
You Retweeted
Dr. Rob Scott discusses
#patient recruitment and#trial burdens@usaic#usaic2019@Boston: prefers to do in house#clinicaltrials & not use CRO as CRO less effective in monitoring trial@AVIVA1950@Pharma_BI
-
You Retweeted
“Some drug platforms are mature enough to fall under the practice of medicine” – Tim Yu of
@harvardmed#USAIC2019 -
You Retweeted
Closing R&D strategies panel at
#USAIC2019 is with NIBR’s@jaybradner Janssen’s@mmammen and Takeda’s Andy Plump. Moderator Martin Mackay (now of newco Rallybio) asks: What are you most excited about?
-
You Retweeted
Talk of indexed pricing model in the US may be a challenge for access to other parts of the world, says a speaker on rare disease panel
#usaic2019 -
You Retweeted
The biggest problem that we have in the industry is the lack of empathy, says Chris Viehbacher
#usaic2019 -
You Retweeted
Tim Yu’s example left a room full of seasoned biopharma R&D execs wowed. More background here: https://eventpilot.us/web/page.php?page=IntHtml&project=ASHG18&id=180124037 …
#USAIC2019 -
You RetweetedMore
#USAIC19 (May 9, Boston) will feature plenary panel on Emerging R&D Strategies moderated by Dr. Martin Mackay, Co-Founder, Rallybio, with@jaybradner of$NVS, Andy Plump of@TakedaPharma,@mmammen of Janssen, Michael Ehler of$BIIB -> register today http://usaindiachamber.org/speaker.php
-
You RetweetedMore
Check out my latest article: Where is Oncology Drug Development Heading Next? Hear From Top KOLs at 13th BioPharma Summit May 9, Boston http://www.usaindiachamber.org https://www.linkedin.com/pulse/where-oncology-drug-development-heading-next-hear-from-karun-rishi … via
@LinkedIn -
You RetweetedMore
Check out my latest article: One in a Million: Emerging Trends in Rare Diseases at 13th annual BioPharma Summit- May 9, Boston http://www.usaindiachamber.org https://www.linkedin.com/pulse/one-million-emerging-trends-rare-diseases-13th-annual-karun-rishi … via
@LinkedIn -
You RetweetedMore
Check out my latest article: Chris Viehbacher, Gurnet Point Capital joins the USAIC Advisory Board. Please join Chris & other leaders at our annual BioPharma Summit, May 9, Boston https://www.linkedin.com/pulse/chris-viehbacher-managing-partner-gurnet-point-capital-karun-rishi … via
@LinkedIn -
You RetweetedMore
Check out my latest article: R&D Panel: BioPharma KOLs Debate R&D Strategies & Trends at 13th annual BioPharma Summit, May 9, Boston http://www.usaindiachamber.org https://www.linkedin.com/pulse/rd-panel-biopharma-kols-debate-strategies-trends-13th-karun-rishi … via
@LinkedIn -
You RetweetedMore
Check out my latest article: What Does The Future Hold For Drug Development & Clinical Trials? Hear Predictions From Top Drug Developers at the 13th BioPharma Summit May Boston 9 https://www.linkedin.com/pulse/what-does-future-hold-drug-development-cts-hear-from-top-karun-rishi … via
@LinkedIn -
You RetweetedMore
USAIC celebrates Biogen@40 https://www.linkedin.com/pulse/usaic-celebrates-biogen40-karun-rishi … via
@LinkedIn -
You RetweetedMore
Value and Access – The Ongoing Debate.The
#USAIC19 BioPharma Summit will feature this special session. Join the discussion with BioPharma KOLs https://www.linkedin.com/pulse/value-access-ongoing-debatethe-usaic19-biopharma-summit-karun-rishi … via@LinkedIn -
You RetweetedMore
BioPharma Manufacturing in the Future: Hear KOLs Debate the Challenges and Opportunities at the 13th annual BioPharma Summit, May 9, Boston https://www.linkedin.com/pulse/biopharma-manufacturing-future-hear-kols-debate-challenges-rishi … via
@LinkedIn -
You RetweetedMore
Our 13th Biopharma & Healthcare Summit has kicked off with introductory remarks from USAIC President Karun Rishi and emcee Dr. Andrew Plump, President of R&D for Takeda.
#USAIC2019#USAIC19
-
You Retweeted
The session is starting as I attend the
#USAIC2019 focused on US-India bio-pharma healthcare summit. The focus is on#ecosystems and#innovation to deliver compelling affordable care with key role for#digital technologies.@USAIC -
You Retweeted
Carl June believes we’re only a few years away from outpatient CAR therapies, with no need for intensive infrastructure with ICU.
#usaic2019 -
You Retweeted
#USAIC2019#USAIC19@pharma_BI@AVIVA1950 Dr. Maus@MGHCancerCenter monitoring data from clinical trial is very important development of new targets multiple drugs multiple mechanism multiple specificities more modification to one cell contamination results
-
You Retweeted
Rare disease taking center stage as technologies mature, panel moderated by CRISPR Therapeutics CEO Samarth Kulkarni
#usaic2019
-
You Retweeted
Enjoyed moderating the panel on manufacturing in the future as bio pharma companies explore ways to deliver drugs at affordable price and address access challenges. Digital innovation in manufacturing and supply chains will be key.
#USAIC2019 -
You Retweeted
Price is part of doing business…if you are not able to define value, you are sunk, says Chris Viehbacher Gurnet Point Capital
#usaic2019 -
You Retweeted
All diseases are unique Your perspective changes when you or someone you love is diagnosed with a life-altering disease –
@davidlucchino#USAIC19 rare diseases panel -
You Retweeted
Arun Singhal, addl secretary, health ministry speaks about Ayushman Bharat, trade margin rationalisation, clinical trial rules at
#usaic2019 meeting -
You Retweeted
Clinical trials in India picking up steadily, says Eswara Reddy, DCGI
#usaic2019
-
You Retweeted
Regulators will “provide complete support” for clinical trials in India provided drug developers meet the new requirements – Drug Controller General of India Eswara Reddy
#USAIC2019
-
You Retweeted
#USAIC19@mmammen discusses prevention and treatment of early disease e.g. precancer The challenge is to work out the commercial model@jaybradner says organize around prevention Early diagnosis / discovery of disease processes saves lives (@revealpharma’s raison d’etre) -
AMAZING EVENT
#USAIC2019@USAIC@pharma_BI @AVIVA11950 13th Annual#BioPharma & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA https://pharmaceuticalintelligence.com/2019/04/30/13th-annual-biopharma-healthcare-summit-thursday-may-9-2019/ … via@Pharma_BI -
Dr. James Bradner, President, Novartis Institutes for BioMedical Research biophysical biochemical protein degradation – rewire disease cells with biomolecules combing propertitie of permiability of small molecules
@USAIC#USAIC2019@pharma_BI@AVIVA1950 -
#usaic2019@USAIC @Pharma_BI@AVIVA1950 World PGD Growth of 4% in India 31%
-
You Retweeted
Takeda R&D Head Andy Plump asks question from audience to peers on stage: “I’ve been in the industry for 18 years and I can’t understand why a clinical trial costs so much. Why does it?”
#USAIC19#USAIC2019
-
You Retweeted
Manufacturing in the age of individualized medicine? We may need a completely different thinking for that says Paul Mckenzie, Biogen
#usaic2019 -
You Retweeted
The so-called low-cost manufacturing edge of India will go away in a few years, says Hari Bhartia, Jubilant…being closer to the customer will be important
#usaic2019 -
You Retweeted
Tricky question: getting patients to cancer centers to participate in clinical trials. Should patients be reimbursed for long travels and other expenses or will it be seen as an inducement?
#usaic2019 -
You Retweeted
A chance to collaborate with my old colleague & friend
@VikasReports! -> another point from same#USAIC2019 panel: AbbVie CMO Rob Scott predicts tele-health solutions for clinical trial patients will be scalable soon -
You Retweeted
Carl June: There are no CAR-T clinical trials in India. But says countries like India could eventually leapfrog to next gen (outpatient) cell therapy which will require less infrastructure + lower COG
#USAIC2019#USAIC19
-
You Retweeted
The 13th Annual BioPharma & Healthcare Summit is being kicked off by Andrew Plump. In his opening remarks, he commented that we should feel privileged as attendees because not even
@JohnCendpts or@jpmorgan is invited to this meeting.#usaic2019@USAIC -
You Retweeted
A well-represented panel of scientists, CEOs and entrepreneurs discuss a range of discovery research from CAR-Ts to small molecules…on the same panel is Arjun Surya of Curadev that licensed a preclinical oncology lead to Takeda.
#usaic2019
-
The promise of India is the largest democracy, the educated workforce the size of the market for therapeutics, access and price, reimbursement and regulation. DCGI the analogue of FDA is very active and innovated the challenge of 1.3 Billion a population of patients
@Pharma_BI -
Great Leader in immunotherapy, Carl June early inventor and endless commitment to patient a Pro for BioPharma
@Pharma_BI@AVIVA1950
-
GREAT Conference of who is who in BioPharma, Boston at the top 500 startats of Biotech in Cambridge, MA ten years afo only a handful, boost by Novartis HQS in Cambridge, MA
@Pharma_BI@AVIVA1950 -
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Frason
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply